Drugs / Acebilustat
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT03964558 | Apr 2019 | — | Celtaxsys, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02233244 | Sep → Oct 2014 | — | Celtaxsys, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01944735 | Sep 2013 → Oct 2014 | cystic fibrosis | Celtaxsys, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01748838 | Dec 2012 → Jul 2013 | lung disorder | Celtaxsys, Inc. | Completed | No outcome recorded |
| Phase 25 trials · 3 missed | ||||||
| Phase 2 | NCT05203835 | Jul 2022 → Oct 2025 | lymphedema | Stanford University | Completed | No outcome recorded |
| Phase 2 | NCT04662060 | Apr 2021 → May 2022 | COVID-19 | Stanford University | Completed | Missed primary |
| Phase 2 | NCT04662086 | Apr 2021 → May 2022 | COVID-19 | Stanford University | Completed | Missed primary |
| Phase 2 | NCT02443688 | Oct 2015 → Apr 2018 | cystic fibrosis | Celtaxsys, Inc. | Completed | Missed primary |
| Phase 2 | NCT02385760 | Apr 2015 → May 2016 | acne | Celtaxsys, Inc. | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Acebilustat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04662060 ↗ |
| Known as | CTX 4430 | “A Placebo Controlled Trial of Acebilustat (CTX 4430) for the Treatment of Human Upper Extremity Lymphedema” NCT05203835 ↗6“Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-Acebilustat (CTX-4430)” NCT03964558 ↗ |
| Known as | EP-501 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297604 ↗ |
| Action | Activate | “potential of CTX-4430 to induce CYP3A activity” NCT02233244 ↗ |
| Action | Inhibit | “Leukotriene A4 hydrolase inhibitor” CHEMBL4297604 ↗ |
| Modality | Small molecule | “novel synthetic small molecule” NCT03964558 ↗ |
| Route | Oral | “administered orally” NCT01748838 ↗ |
| Target | LTA4H | “Leukotriene A4 hydrolase inhibitor” CHEMBL4297604 ↗ |